c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs
J. Clin. Invest. Hisashi Takasu, et al. 116:528 doi:10.1172/JCI24742 [Go to this article.]

Figure 9
A novel vitamin D analog, DD281, inhibits osteoclast differentiation and increases BMD more potently than 1α,25(OH)₂D₃ in vivo. (A) Structures of 1α,25(OH)₂D₃ and its analog, DD281. (B) Ovariectomized (OVX) C57BL/6J mice were treated orally with the indicated doses of 1α,25(OH)₂D₃ or its analog DD281 for 4 weeks, and urinary calcium excretion was determined for the final 24 hours. *P < 0.05 versus OVX group with vehicle treatment, ^#P < 0.05 versus sham group, n = 8 each group. (C) BMD at the lumbar vertebrae was determined. *P < 0.05 versus OVX group with vehicle treatment, **P < 0.005 versus OVX group with vehicle treatment, ***P < 0.0005 versus OVX group with vehicle treatment, ^#P < 0.05 versus sham group, n = 8 each group.